Table 3.
ER results among different groups of patients
| Parameter | ER: N (%) 352 stained tumours | |||
|---|---|---|---|---|
| Positive (% in row or mean and standard deviation) | Negative (% in row or mean and standard deviation) | ER-negative vs. ER-positive crude RR (95% CI) | ER-negative vs. ER-positive adjusted* RR (95% CI) | |
| Total population n = 352 | 230 (65.3) | 122 (34.7) | ||
| Age [years] (mean and standard deviation) | 43.0 (13.7) | 40.1 (12.6) | Increase 5 yrs 1.02 (0.98–1.01) | Increase 5 yrs 0.94 (0.89–1.00) |
| Tumour size [cm] (mean and standard deviation; n = 168 results available) | 5.47 (3.3) | 6.06 (3.3) | Increase 1 cm 1.03 (0.98–1.08) | Increase 1 cm 1.03 (0.97–1.08) |
| Place of origin | ||||
| Addis Ababa | 123 (67.2) | 60 (32.8) | Reference | Reference |
| Non-Addis Ababa | 89 (63.6) | 51 (36.4) | 1.11 (0.82–1.50) | 1.03 (0.76–1.41) |
| Unknown | 18 (62.1) | 11 (37.9) | 1.16 (0.69–1.93) | 1.10 (0.66–1.82) |
| Menopausal status | ||||
| Premenopausal | 89 (61.4) | 56 (38.6) | 1.17 (0.87–1.59) | 0.81 (0.54–1.23) |
| Postmenopausal | 104 (67.1) | 51 (32.9) | Reference | Reference |
| unknown | 37 (71.2) | 15 (28.8) | 0.88 (0.54–1.42) | 0.62 (0.36–1.07) |
| Stage (UICC) | ||||
| 1 and 2 | 24 (68.6) | 11 (31.4) | 0.89 (0.53–1.52) | 0.92 (0.54–1.56) |
| 3 | 109 (64.9) | 59 (35.1) | Reference | Reference |
| 4 | 48 (67.6) | 23 (32.4) | 0.92 (0.62–1.37) | 0.96 (0.65–1.42) |
| Unknown | 49 (62.8) | 29 (37.2) | 1.06 (0.74–1.51) | 1.06 (0.75–1.51) |
| Histology | ||||
| Ductal | 171 (64.5) | 94 (35.5) | Reference | Reference |
| Lobular | 12 (60.0) | 8 (40.0) | 1.13 (0.64–1.98) | 1.05 (0.60–1.85) |
| Other/unspecified | 47 (70.2) | 20 (29.8) | 0.84 (0.56–1.26) | 0.83 (0.56–1.24) |
| Progesterone receptor | ||||
| Positive | 162 (92.0) | 14 (8.0) | Reference | Reference |
| Negative | 62 (36.9) | 106 (63.1) | 7.93 (4.74–13.28) | 7.81 (4.66–13.09) |
| Unknown | 6 (75.0) | 2 (25.0) | 3.14 (0.86–11.55) | 3.47 (0.94–12.78) |
| Basis of hormone receptor diagnosis | ||||
| Primary operation | 117 (67.2) | 57 (32.8) | Reference | Reference |
| Recurrence | 62 (58.5) | 44 (41.5) | 1.12 (0.96–1.31) | 1.08 (0.91–1.27) |
| Unknown basis | 51 (70.8) | 21 (29.2) | 0.89 (0.59–1.35) | 0.87 (0.58–1.33) |
| Patho-specimen for diagnosis | ||||
| FNAC+ | 92 (72.4) | 35 (27.6) | 0.67 (0.48–0.94) | 0.71 (0.51–0.98) |
| Tumour specimen | 114 (59.1) | 79 (40.9) | Reference | Reference |
| Unknown | 24 (75.0) | 8 (25.0) | 0.61 (0.33–1.14) | 0.61 (0.33–1.16) |
+FNAC – fine needle aspiration cytology.
*Risk ratios were adjusted for age and stage, unless this was the variable of interest, RR for age was not adjusted.